Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity.: Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation

被引:57
作者
Nicolaes, GAF [1 ]
Villoutreix, BO [1 ]
Dahlbäck, B [1 ]
机构
[1] Univ Lund, Malmo Univ Hosp, Dept Clin Chem, Wallenberg Lab, S-20502 Malmo, Sweden
关键词
D O I
10.1021/bi991165r
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Coagulation factor V (FV) circulates in two forms, FV1 and FV2, having slightly different molecular masses and phospholipid-binding properties. The aim was to determine whether this heterogeneity is due to the degree of glycosylation of Asn(2181). FVa1 and FVa2 were isolated and digested with endoglycosidase PNGase F. As judged by Western blotting, the FVa2 light chain contained two N-linked carbohydrates, whereas FVa1 contained three. Wild-type FV and three mutants, Asn(2181)Gln, Ser(2183)Thr, and Ser(2183)Ala, were expressed in COS1 cells, activated by thrombin, and analyzed by Western blotting. Wild-type FVa contained the 71 kDa-74 kDa doublet, whereas the Asn(2181)Gln and Ser(2183)Ala mutants contained only the 71 kDa light chain. In contrast, the Ser(2183)Thr mutant gave a 74 kDa light chain. This demonstrated that the third position in the Asn-X-Ser/Thr consensus affects glycosylation efficiency, Thr being associated with a higher degree of glycosylation than Ser. The Ser(2183)Thr mutant FVa was functionally indistinguishable from plasma-purified FVa1, whereas Asn(2181)Gln and Ser(2183)Ala mutants behaved like FVa2. Thus, the carbohydrate at Asn2181 impaired the interaction between FVa and the phospholipid membrane, an interpretation consistent with a structural analysis of a three-dimensional model of the C2 domain and the position of a proposed phospholipid-binding site. In conclusion, we show that the FV1-FV2 heterogeneity is caused by differential glycosylation of Asn(2181) related to the presence of a Ser rather than a Thr at the third position in the consensus sequence of glycosylation.
引用
收藏
页码:13584 / 13591
页数:8
相关论文
共 53 条
[41]  
SUZUKI K, 1983, J BIOL CHEM, V258, P1914
[42]  
SUZUKI K, 1982, J BIOL CHEM, V257, P6556
[43]  
TANS G, 1991, BLOOD, V77, P2641
[44]  
TANS G, 1994, J BIOL CHEM, V269, P15969
[45]   The c-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V [J].
Thorelli, E ;
Kaufman, RJ ;
Dahlbäck, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (26) :16140-16145
[46]   Cleavage requirements for activation of factor V by factor Xa [J].
Thorelli, E ;
Kaufman, RJ ;
Dahlback, B .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 247 (01) :12-20
[47]  
TRACY PB, 1982, BLOOD, V60, P59
[48]  
VANHEIJNE, 1994, ANN REV BIOPHYS BIOM, V23, P167
[49]  
Varadi K, 1996, THROMB HAEMOSTASIS, V76, P208
[50]   Molecular models for the two discoidin domains of human blood coagulation factor V [J].
Villoutreix, BO ;
Bucher, P ;
Hofmann, K ;
Baumgartner, S ;
Dahlback, B .
JOURNAL OF MOLECULAR MODELING, 1998, 4 (08) :268-275